Brussels, Belgium, July 5, 2013
Merodis is pleased to announce that it successfully advised Cardio3 BioSciences (C3BS) in having secured PMV’s (Participatie Maatschappij Vlaanderen) investment of EUR 9,5m in the company. The funds will be used to co-finance the company’s Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for its lead compound C-Cure®.
Dr Christian Homsy, CEO of Cardio3 BioSciences, said: ’’Merodis has been instrumental in getting an additional corner stone investor such as PMV on board. I am very pleased that since January 2013 Merodis worked on securing the participation of PMV that has now concluded into our succesfull IPO.’’
Belgian Biotechnology company Cardio3 BioSciences is a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases. The CHART-1 trial represents the world’s first Phase III trial for a pre-programmed cellular therapy targeting heart failure and builds on the successful outcome of the Phase II trial of which the results were recently published in the Journal of the American College of Cardiology (JACC).
For more information, please contact:
firstname.lastname@example.org , +32 495 38 17 81
email@example.com , +32 495 58 68 98